Gout Treatment Guidelines Revamped After New Clinical Guidance

The updated 2020 guidelines from the American College of Rheumatology focus on establishing a standard treat-to-target urate lowering therapy.

3:08 PM

Author | Jordyn Imhoff

drawing of stethoscope
Image by Stephanie King.

Since the American College of Rheumatology last released the treatment guidelines for gout in 2012, new clinical evidence based on the latest clinical trials has prompted releasing updated guidelines that will improve patient care for the affected population. Standardization of a treat-to-target strategy for urate lowering therapy is the key focus because of its benefit for all patients with gout.

Gout, the most common form of inflammatory arthritis, is a painful, potentially disabling condition caused by having too much uric acid in the body. Uric acid buildup causes chronic inflammation leading to damage in the joints.

"The guidelines include expanded implications for starting urate lowering therapy and a greater emphasis to use allopurinol as the first line agent for all patients with gout that require urate lowering therapy, including those patients with chronic kidney disease," says Puja Khanna, M.D., MPH, a rheumatologist at Michigan Medicine. "It also broadened recommendations about who needs HLA-B*5801 testing prior to starting allopurinol." HLA-B*5901 is a genetic risk factor in specific populations.

The new guidelines recommend a management strategy of starting with a low-dose of a urate lowering medication and increasing the dosage to achieve and maintain a serum urate level of less than 6 mg/dL. This strategy, compared to the 2012 fixed-dose strategy, reduces the risk of treatment-related adverse effects, like flares and other side effects. Other recommendations include:

  • Using an anti-inflammatory prophylaxis (e.g., colchicine, NSAIDs, prednisone/prednisolone) when starting urate lowering therapy for at least three to six months rather than less than three months.
  • Considering urate lowering therapy for patients with infrequent gout flares or after their first gout flare if they also have moderate to severe chronic kidney disease (greater than or equal to stage three), marked hyperuricemia (serum urate greater than 9 mg/dL) or kidney stones.

The guidelines were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The updated and expanded recommendations can be viewed at American College of Rheumatology.


More Articles About: Lab Notes Health Care Delivery, Policy and Economics Arthritis Rheumatology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories drawing of pills in blue ink with lab note written on bottom right in yellow and navy blue
Health Lab
Patient Support Programs for Painful Conditions May Reduce Opioid Use
Study in people taking a biologic drug for autoimmune diseases shows association of patient support programs with reduced chance of starting opioid pain medicines or continuing on them.
girl hugging teddy bear with alcohol bottles on ground
Health Lab
1 in 4 kids live with parents who have alcohol or other drug problems
Children living with parents who have addiction issues, also called substance used disorder, have higher risks later in life. A new study shows 1 in 4 currently live in such households.
2025 blocks with stethoscope
Health Lab
Top 10 things to know about your health costs right now
From Medicare prescription costs and medical debt rules to actions that the Supreme Court, Congress and President Trump have taken or could take, a guide to health policies that affect many people.
two hearts next to each other with small figure people inside and out of it
Health Lab
How neutrophil calprotectin unmasks future atherosclerotic heart disease risk
The immune system is showing evidence of playing a roll in the emergence of atherosclerotic cardiovascular disease. A rush of neutrophils, or immune cells to the site could be an explanation for how this condition forms as well as how to prevent this heart disease in the future.
american flag with stethoscope on it
Health Lab
What does Medicaid do?
Medicaid provides health insurance coverage for tens of millions of American children and adults. Research on its impact shows positive effects in many ways.
lungs beating pink and orange and yellow and white circles floating around
Health Lab
Protein found in rheumatic diseases causes inflammation in COVID-19 patients
Research on the inflammatory mediator called sCD13 has identified this molecule and its receptors as new targets for treatment of autoimmune rheumatic diseases. The data suggests that sCD13 may also be of great importance in severe complications of COVID-19.